Experimental drugs match or beat Mounjaro in weight loss trials, review finds

ANBAR, Iraq — Experimental obesity drugs Retatrutide and Amicretin produced weight loss comparable to or greater than Eli Lilly's Mounjaro in clinical trials, according to a review of 38 studies covering more than 25,000 participants. Researchers at McGill University and Montreal's Jewish General Hospital found that Retatrutide led to about a 25% reduction in body weight over 48 weeks, while Amicretin achieved similar results in 36 weeks. By comparison, tirzepatide, the active ingredient in Mounjaro, delivered more than 20% weight loss after 17 months of treatment. Semaglutide injections such as Wegovy and Ozempic produced up to 18.7% reductions over comparable periods. Both Retatrutide and Amicretin remain in clinical trials and have not yet been approved for widespread use. The researchers said drugs targeting multiple hormone pathways appeared to produce greater weight loss. The review also documented gastrointestinal side effects for the experimental treatments, including nausea, vomiting, diarrhea and constipation.